Provided by Tiger Fintech (Singapore) Pte. Ltd.

Assembly Biosciences

17.08
-0.2300-1.33%
Volume:18.92K
Turnover:324.44K
Market Cap:130.45M
PE:-2.79
High:17.40
Open:17.21
Low:16.81
Close:17.31
Loading ...

Assembly Biosciences Reports Positive Phase 1b Trial Results

TIPRANKS
·
Yesterday

Assembly Biosciences Says ABI-4334 Phase 1b Trial Showed 'Strong' Antiviral Activity in Chronic Hepatitis B

MT Newswires Live
·
25 Jun

BRIEF-Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Assembly Modulator in Chronic Hepatitis B

Reuters
·
25 Jun

Assembly Biosciences Inc - Abi-4334 Well-Tolerated With Favorable Safety Profile

THOMSON REUTERS
·
25 Jun

Assembly Biosciences Reports Positive Topline Results From Phase 1B Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator Abi-4334 in Chronic Hepatitis B

THOMSON REUTERS
·
25 Jun

BRIEF-Assembly Biosciences Inc - Jeanette M. Bjorkquist Appointed Principal Financial Officer On June 5- SEC Filing

Reuters
·
10 Jun

Assembly Biosciences Inc - Jeanette M. Bjorkquist Appointed Principal Financial Officer on June 5- SEC Filing

THOMSON REUTERS
·
10 Jun

Assembly Biosciences Inc. Conducted Annual Stockholders Meeting

Reuters
·
10 Jun

Mizuho Securities Sticks to Its Buy Rating for Assembly Biosciences (ASMB)

TIPRANKS
·
22 May

Mizuho Cuts Price Target on Assembly Biosciences to $29 From $36, Keeps Outperform Rating

MT Newswires Live
·
21 May

Assembly Biosciences Inc : Mizuho Cuts Target Price to $29 From $36

THOMSON REUTERS
·
21 May

Assembly Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Assembly Biosciences Q1 EPS $(1.17) Beats $(1.60) Estimate, Sales $9.42M Beat $7.63M Estimate

Benzinga
·
09 May

Assembly Biosciences announces preclinical data, to present at EASL Congress

TIPRANKS
·
07 May

Assembly Biosciences Inc expected to post a loss of $1.60 a share - Earnings Preview

Reuters
·
02 May

Assembly Biosciences (NASDAQ:ASMB) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.
·
02 May

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

GlobeNewswire
·
09 Apr

Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround

Zacks
·
08 Apr

Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock?

Zacks
·
27 Mar

Assembly Biosciences Inc : Guggenheim Initiates Coverage With Buy Rating; Target Price $31

THOMSON REUTERS
·
25 Mar